Harvest Fund Management Co. Ltd Acquires New Position in 10x Genomics, Inc. (NASDAQ:TXG)

Harvest Fund Management Co. Ltd acquired a new stake in shares of 10x Genomics, Inc. (NASDAQ:TXG) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 1,178 shares of the company’s stock, valued at approximately $66,000.

Other institutional investors have also modified their holdings of the company. UMB Bank n.a. boosted its stake in 10x Genomics by 51.6% during the 4th quarter. UMB Bank n.a. now owns 782 shares of the company’s stock valued at $44,000 after purchasing an additional 266 shares during the period. AIA Group Ltd boosted its stake in 10x Genomics by 0.9% during the 4th quarter. AIA Group Ltd now owns 41,369 shares of the company’s stock valued at $2,315,000 after purchasing an additional 365 shares during the period. Xponance Inc. lifted its stake in shares of 10x Genomics by 3.2% in the 3rd quarter. Xponance Inc. now owns 13,060 shares of the company’s stock worth $539,000 after acquiring an additional 400 shares during the period. Parametrica Management Ltd lifted its stake in shares of 10x Genomics by 3.4% in the 3rd quarter. Parametrica Management Ltd now owns 15,300 shares of the company’s stock worth $631,000 after acquiring an additional 500 shares during the period. Finally, Mirador Capital Partners LP lifted its stake in shares of 10x Genomics by 1.9% in the 4th quarter. Mirador Capital Partners LP now owns 27,885 shares of the company’s stock worth $1,560,000 after acquiring an additional 521 shares during the period. Institutional investors own 84.68% of the company’s stock.

Analyst Ratings Changes

TXG has been the topic of a number of research reports. Deutsche Bank Aktiengesellschaft dropped their target price on shares of 10x Genomics from $60.00 to $55.00 and set a “buy” rating on the stock in a report on Thursday, April 18th. Stifel Nicolaus dropped their target price on shares of 10x Genomics from $68.00 to $63.00 and set a “buy” rating on the stock in a report on Friday, February 16th. Finally, Barclays dropped their target price on shares of 10x Genomics from $55.00 to $45.00 and set an “overweight” rating on the stock in a report on Wednesday, April 10th. One research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat.com, 10x Genomics has an average rating of “Moderate Buy” and an average price target of $60.22.

Insider Buying and Selling

In other 10x Genomics news, insider Benjamin J. Hindson sold 2,613 shares of the firm’s stock in a transaction that occurred on Thursday, February 22nd. The shares were sold at an average price of $46.34, for a total transaction of $121,086.42. Following the sale, the insider now directly owns 283,059 shares in the company, valued at approximately $13,116,954.06. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In other news, insider Benjamin J. Hindson sold 2,613 shares of 10x Genomics stock in a transaction that occurred on Thursday, February 22nd. The shares were sold at an average price of $46.34, for a total value of $121,086.42. Following the sale, the insider now directly owns 283,059 shares in the company, valued at $13,116,954.06. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Serge Saxonov sold 2,821 shares of 10x Genomics stock in a transaction that occurred on Thursday, February 22nd. The shares were sold at an average price of $46.34, for a total transaction of $130,725.14. Following the completion of the sale, the chief executive officer now owns 847,560 shares in the company, valued at $39,275,930.40. The disclosure for this sale can be found here. Insiders have sold 12,959 shares of company stock valued at $592,806 in the last 90 days. 10.65% of the stock is owned by insiders.

10x Genomics Trading Down 2.3 %

NASDAQ TXG opened at $26.90 on Friday. The company has a fifty day simple moving average of $38.12 and a 200 day simple moving average of $42.60. The company has a market cap of $3.21 billion, a P/E ratio of -12.40 and a beta of 1.90. 10x Genomics, Inc. has a 1 year low of $26.30 and a 1 year high of $63.57.

10x Genomics (NASDAQ:TXG) last announced its quarterly earnings data on Thursday, February 15th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.05). 10x Genomics had a negative net margin of 41.17% and a negative return on equity of 28.82%. The business had revenue of $183.98 million during the quarter, compared to analyst estimates of $182.73 million. During the same quarter in the prior year, the company posted ($0.15) EPS. The company’s quarterly revenue was up 17.8% compared to the same quarter last year. Equities research analysts forecast that 10x Genomics, Inc. will post -1.47 EPS for the current fiscal year.

About 10x Genomics

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.